On October 18, 2016 Sirenas, LLC and the California Institute for Biomedical Research (Calibr) reported that they are collaborating in an effort to discover and develop small molecules in oncology, neuroscience, regenerative medicine and neglected disease (Press release, Sirenas, OCT 18, 2016, View Source [SID1234517478]). Sirenas will provide Calibr with access to its marine-derived chemical diversity, AtlantisTM data mining technology, and synthetic chemistry expertise. Calibr will evaluate compounds in a series of novel biological assays and preclinical disease models.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Sirenas has combined the rich chemical diversity found in marine organisms with enabling analytics and informatics to create a powerful platform that we believe could be valuable in targeting some of the most intractable disease phenotypes," said Pete Schultz, President and CEO of Calibr. "We are delighted to pair the tools and expertise we have developed at Calibr with Sirenas’ technology to tackle unmet public health needs."
"Marine organisms have evolved over hundreds of millions of years in highly competitive environments, which has allowed them to evolve very diverse, potent chemistry," said Eduardo Esquenazi, Ph.D., founder and CEO of Sirenas. "In the past, the challenges of identifying and translating those compounds has hindered their pursuit, but we have focused on building an approach that can quickly and cost effectively bring forth these novel compounds into new avenues of drug discovery research. The collaboration with Calibr provides significant biological capabilities to better understand how our compounds work against a number of disease targets."
Financial terms of the collaboration were not disclosed, but the parties plan to co-develop promising leads through definitive preclinical and early clinical studies.